Vaxart (NASDAQ:VXRT) Stock, Quote.Headers.trade-ideas

Vaxart

Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

AIHS

AMSC

ARAI

CARM

CNET

DPRO

GELS

GETY

GLYC

GTLB

IMNN

INEO

KBSX

NCNA

SFIX

VTAK

VXRT

YSXT

Why Stitch Fix Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket

Wall Street

Equities

CASY

CHWY

CVGW

ORCL

PLAY

SAIL

VSCO

US Stocks Likely To Open Lower Ahead Of May Inflation Report: S&amp;P 500 Still In A 31-Month-Long Bull Market, &#39;Better Times Are Coming,&#39; Says Expert

Analyst Color

Biotech

News

Health Care

Initiation

Analyst Ratings

Movers

Trading Ideas

General

Oppenheimer initiates Vaxart coverage with an Outperform rating and $4 price target, citing a bullish outlook on its oral vaccines for COVID-19 and norovirus.

Oral Vaccine Focused Penny Stock Vaxart Is &#39;Uniquely Positioned&#39;, Analyst Sees Almost 83% Upside

Vaxart Inc

Markets

Press Releases

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vaxart Announces Adjournment of Annual Meeting of Stockholders

Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial

Vaxart Answers Additional Frequently Asked Questions from Retail Investors

Management

Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders

Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial

Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology

Vaxart Announces Preliminary Results of Annual Meeting of Stockholders

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Agenus

Alector

Anixa Biosciences

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

BeyondSpring

Caribou Biosciences

Elicio Therapeutics

Fate Therapeutics

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

TuHURA Biosciences

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Korro Bio

Lexeo Therapeutics

Lyell Immunopharma

Molecular Partners AG - American Depositary Shares

Molecular Partners

Nkarta

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

RAPT Therapeutics

AVITA Medical

Protara Therapeutics, Inc. - Common Stock

Protara Therapeutics

Theratechnologies

B. Riley Securities

Oppenheimer

Cantor Fitzgerald

Comments

Vaxart

Vaxart (NASDAQ:VXRT) Stock, Quote.Headers.trade-ideas

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell